非小细胞肺癌、黑色素瘤与肾细胞癌脑转移患者中免疫检查点抑制剂与单次立体定向放射外科的同期应用
该多中心回顾性分析纳入657例非小细胞肺癌、肾细胞癌或黑色素瘤脑转移患者共4182个转移灶,评估单次立体定向放射外科(SRS)与免疫检查点抑制剂(ICI)同期应用时放射性坏死(RN)风险。任意级别RN的1年、2年发生率分别为6.4%、9.9%,症状性RN分别为4.8%、7.2%;按V12 Gy分层后三组间差异有统计学意义(P<0.001),但校正治疗时机后任意级别RN或症状性RN均无显著差异。作者结论认为同期给药不增加RN风险,ICI可在SRS后4周内安全给药。
要点
- 任意级别RN的1年、2年发生率分别为6.4%、9.9%,症状性RN分别为4.8%、7.2%。
- V12 Gy分层三组任意级别RN的1年发生率分别为3.7%、10.3%、12.6%(P<0.001)。
- 校正治疗时机后,同期与非同期给药相比任意级别RN或症状性RN均无统计学显著差异。
核心结论
- SRS与ICI联合应用时任意级别RN和症状性RN风险均较低,同期给药未增加该风险。
- 作者结论认为ICI可在SRS后4周内安全给药。
- 基于V12 Gy识别出三个风险组,临床医生可考虑以此进一步降低RN发生率。
研究设计与样本
- 多中心回顾性分析,纳入来自11家国际机构的657例非小细胞肺癌、肾细胞癌或黑色素瘤脑转移患者,共4182个脑转移灶,接受SRS与ICI治疗。
- 采用竞争风险模型(死亡作为竞争风险)进行任意级别RN和症状性RN的时间-事件分析。
- 次要分析采用递归分割分析(RPA)进行模型开发,并分析候选模型循环,选择最高保真度模型,将RPA识别的脑V12 Gy阈值纳入竞争风险分析。
主要发现
- 全部患者中位随访13.4个月;同期给药组中位随访12.8个月,非同期给药组14.1个月(P=0.03)。
- 患者中位年龄66岁,中位Karnofsky体能状态评分90分。
- 任意级别RN的1年、2年发生率分别为6.4%、9.9%;症状性RN分别为4.8%、7.2%。
- RPA识别的V12 Gy三个风险组为:<12 cm³组、12 cm³≤V12 Gy≤20 cm³组、V12 Gy>20 cm³组。
- 任意级别RN的1年发生率分别为3.7%(V12 Gy<12 cm³)、10.3%(12 cm³≤V12 Gy≤20 cm³)、12.6%(V12 Gy>20 cm³),2年发生率分别为7.5%、13.8%、15.4%(P<0.001);症状性RN的1年发生率分别为2.4%、8.9%、10.3%,2年发生率分别为4.4%、12.4%、13.1%(P<0.001)。
关键数值与推荐
- RPA识别的V12 Gy风险分层阈值:<12 cm³、12–20 cm³(含12和20)、>20 cm³。
- 任意级别RN:V12 Gy<12 cm³组1年3.7%、2年7.5%;12–20 cm³组1年10.3%、2年13.8%;>20 cm³组1年12.6%、2年15.4%(P<0.001)。
- 症状性RN:V12 Gy<12 cm³组1年2.4%、2年4.4%;12–20 cm³组1年8.9%、2年12.4%;>20 cm³组1年10.3%、2年13.1%(P<0.001)。
临床怎么用
- 作者结论认为ICI可在SRS后4周内安全给药。
- 作者指出基于V12 Gy的三个风险组,临床医生可考虑以此进一步降低RN发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICI) are highly effective treatments for brain metastases, particularly when these therapies are administered concurrently. However, there are limited data reporting the risk of radiation necrosis (RN) in this setting. METHODS AND MATERIALS: Patients with brain metastases from primary non-small cell lung cancer, renal cell carcinoma, or melanoma treated with SRS and ICI were considered. Time-to-event analyses were conducted for any grade RN and symptomatic RN (SRN) with death incorporated as a competing risk. As a secondary analysis, recursive partitioning analysis (RPA) was used for model development, and a loop of potential models was analyzed, with the highest-fidelity model selected. Brain V12 Gy thresholds identified on RPA were then incorporated into the competing risks analysis. Concurrent SRS and ICI administration. RESULTS: Six hundred fifty-seven patients with 4182 brain metastases across 11 international institutions were analyzed. The median follow-up for all patients was 13.4 months. The median follow-up was 12.8 months and 14.1 months for the concurrent and nonconcurrent groups, respectively (P = .03). The median patient age was 66 years, and the median Karnofsky Performance Status was 90. In patients with any grade RN, 1- and 2-year rates were 6.4% and 9.9%, respectively. In patients with SRN, 1- and 2-year rates were 4.8% and 7.2%, respectively. On RPA, the highest-fidelity models consistently identified V12 Gy as the dominant variable predictive of RN. Three risk groups were identified by V12 Gy: (1) < 12 cm3; (2) 20 cm3 ≥ V12 Gy ≥ 12 cm3; (3) V12 Gy > 20 cm3. In patients with any grade RN, 1-year rates were 3.7% (V12 Gy < 12 cm3), 10.3% (20 cm3 ≥ V12 Gy ≥ 12 cm3), and 12.6% (V12 Gy > 20 cm3); the 2-year rates were 7.5% (V12 Gy < 12 cm3), 13.8% (20 cm3 ≥ V12 Gy ≥ 12 cm3), and 15.4% (V12 Gy > 20 cm3) (P < 0.001). In patients with any SRN, 1-year rates were 2.4% (V12 Gy < 12 cm3), 8.9% (20 cm3 ≥ V12 Gy ≥ 12 cm3), and 10.3% (V12 Gy > 20 cm3); the 2-year rates were 4.4% (V12 Gy < 12 cm3), 12.4% (20 cm3 ≥ V12 Gy ≥ 12 cm3), and 13.1% (V12 Gy > 20 cm3; P < 0.001). There were no statistically significant differences in rates of any grade RN or SRN when accounting for therapy timing for all patients and by V12 risk group identified on RPA. CONCLUSIONS: The use of SRS and ICI results in a low risk of any grade RN and SRN. This risk is not increased with concurrent administration. Therefore, ICI can safely be administered within 4-weeks of SRS. Three risk groups based on V12 Gy were identified, which clinicians may consider to further reduce rates of RN.
引用
- Lehrer EJ, Kowalchuk RO, Gurewitz J, et al. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases. Int J Radiat Oncol Biol Phys. 2023. PMID: 36690161. doi:10.1016/j.ijrobp.2023.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。